HEOR Evidence Strategy for Budget Planning: Framework, Checklist & Example

Planning budgets for health economics and outcomes research (HEOR) requires a clear HEOR evidence strategy that ties evidence generation to payer needs, regulatory expectations, and commercial timelines. This guide explains how to rethink evidence priorities so limited funds produce maximum value across dossiers, health technology assessment (HTA) submissions, and real-world evidence (RWE) programs.

Why an HEOR evidence strategy matters for budget planning

Budget decisions that treat HEOR as a line-item rather than a strategic lever often underfund studies that influence coverage and pricing. An HEOR evidence strategy defines which studies (e.g., cost-effectiveness models, budget impact analyses, observational RWE, patient-reported outcomes) are highest priority, when to sequence them, and how to allocate the budget across evidence streams to support reimbursement, pricing negotiations, and post-market commitments.

HEOR evidence strategy: The VALUE-BUDGET framework

The VALUE-BUDGET framework offers a repeatable way to translate strategic objectives into a prioritized HEOR budget. The framework has six components:

• V — Value Questions: Identify the reimbursement and clinical questions decision-makers will ask (e.g., comparative effectiveness, QALYs, budget impact).
• A — Audience Mapping: Map payers, HTA bodies, and clinical opinion leaders to evidence needs and timing.
• L — Level of Evidence: Determine required evidence level (modeling, RCT subgroup analysis, RWE) for each audience.
• U — Use Case Priority: Rank use cases (launch dossier, price negotiations, post-market safety) by expected ROI.
• E — Evidence Mix: Allocate the budget across methods (economic models, observational studies, PRO collection, registries) to cover top priorities.
• BUDGET — Build Buffer & Timing: Reserve contingency funds for unexpected requests and align spend with milestone timelines.

How to apply the VALUE-BUDGET framework

Start with stakeholder workshops to list decision questions and then map those questions to evidence types. Use scoring (impact vs. cost vs. time-to-completion) to rank projects. The output is a budgeted, sequenced plan that shows what to fund now vs. later.

Checklist: Six budget planning actions for HEOR teams

• 1) Inventory existing evidence and identify gaps tied to payer questions.
• 2) Prioritize studies using impact × probability of influencing reimbursement.
• 3) Allocate at least one contingency tranche (5–15%) for rapid-response RWE or analyses.
• 4) Sequence high-impact, low-cost analyses early (e.g., secondary analyses, meta-analyses).
• 5) Define clear success metrics (HTA acceptance, price uplift, formulary placement).
• 6) Review and update the plan quarterly with cross-functional governance.

Real-world example: Allocating a $1M HEOR budget for a new diabetes therapy

Scenario: A mid-size company has $1M to support market access over 18 months. Using the VALUE-BUDGET framework, the plan could look like:

• $300k — Economic model and sensitivity analyses required for HTA dossiers.
• $250k — Claims database analysis to generate RWE on utilization and comparative outcomes.
• $150k — Prospective PRO collection embedded in an ongoing extension study.
• $150k — Budget impact analysis tailored to top five national payers.
• $100k — Rapid-response analytic reserve for payer questions after launch.
• $50k — Stakeholder engagement and advisory boards to validate assumptions.

This allocation prioritizes modeling and RWE that directly influence HTA and payer decisions while reserving funds for rapid evidence generation after launch.

Practical tips for optimizing HEOR budget allocation

• Tip 1: Start with payer evidence requirements — adapt designs to regional HTA standards to avoid rework.
• Tip 2: Use staged investments — fund analyses that unlock further funding (e.g., a small RWE feasibility study that justifies a larger registry).
• Tip 3: Reuse data assets — prioritize projects that create reusable models, datasets, or code to lower marginal costs.
• Tip 4: Build cross-functional gates — require business-case approval before committing large external spend.

Trade-offs and common mistakes

Key trade-offs

• Depth vs. breadth: In-depth randomized substudies increase internal validity but consume budget that could instead fund multiple pragmatic RWE projects with broader generalizability.
• Speed vs. rigor: Fast-turnaround analyses may answer immediate payer questions but may not be accepted by HTA bodies that demand more rigorous methodology.
• Centralized vs. decentralized spend: Centralized HEOR budgeting ensures strategic alignment; decentralized teams may respond faster to local needs but risk duplicative spending.

Common mistakes to avoid

• Funding studies without mapping the question to the decision-maker — leads to evidence that doesn’t move the needle.
• Underestimating post-market evidence requirements — many countries require registry or RWE commitments that can be costly.
• Failing to budget for stakeholder engagement — payers and HTA reviewers often expect pre-submission interaction.

Related concepts, data sources, and standards

When building an HEOR evidence strategy, consider terminology and data sources such as cost-effectiveness analysis, budget impact analysis, real-world data (claims, EHR, registries), QALYs, HTA submission checklists, and modeling best practices. For reference on good practice in outcomes research, review resources from major standards organizations such as ISPOR: ISPOR.

Core cluster questions (targets for related articles)

• How to map payer evidence needs to HEOR study design
• When to invest in real-world evidence versus randomized studies
• How to build a budget impact model that supports price negotiations
• Best practices for sequencing HEOR studies across a product lifecycle
• How to create reusable HEOR assets to reduce long-term costs

Governance and measurement

Set up a governance cadence that reviews spending against milestones and outcome metrics: HTA acceptance rate, time to formulary listing, price achieved, and sensitivity of reimbursement decisions to new evidence. Incorporate these metrics into quarterly budget reviews to reallocate funds where evidence is most effective.

Implementing changes: a short roadmap

• Month 0–1: Stakeholder mapping and evidence gap analysis.
• Month 1–2: Prioritization workshop and VALUE-BUDGET plan creation.
• Month 2–6: Commission high-priority, short-duration projects and build models.
• Quarterly: Review outcomes and reallocate contingency funds.

FAQ

What is an HEOR evidence strategy and why is it critical to budget planning?

An HEOR evidence strategy defines which types of evidence are needed to answer payer and HTA questions, prioritizes them by likely impact on access and pricing, and sequences studies to match business timelines—ensuring that limited budget delivers maximum commercial and reimbursement value.

How much of the HEOR budget should be reserved for real-world evidence planning?

Reserve a contingency tranche of roughly 5–15% for RWE or rapid-response analyses. The exact percentage depends on product risk profile and expected post-market commitments required by regulators or payers.

When should an economic model be developed in relation to RWE generation?

Develop a core economic model early to structure assumptions and identify key data gaps; update the model as RWE accrues to improve credibility and reduce uncertainty in HTA submissions.

How to prioritize between multiple HEOR study proposals with limited funds?

Score proposals using impact (effect on access/pricing), feasibility (time and data availability), and cost. Prioritize high-impact, feasible projects that reduce the greatest decision uncertainty for payers.

What governance structure supports an effective HEOR evidence strategy?

A cross-functional steering committee with representatives from market access, medical affairs, regulatory, and commercial should meet quarterly to review evidence milestones, reallocate budget, and approve contingency uses.